A novel anticoagulation treatment protocol using unfractionated heparin for coronavirus disease 2019 patients in...

Area of Science:

• Medical Research
• Infectious Diseases
• Cardiovascular Thrombosis

Background:

• Hypercoagulability is a key factor in COVID-19 pathogenesis, increasing thrombosis risk.
• Anticoagulation therapy may reduce mortality in COVID-19 patients, but optimal strategies, particularly with unfractionated heparin (UFH), remain unclear.
• Current anticoagulation practices in Japan need to be adapted to the latest evidence for COVID-19 management.

Purpose of the Study:

• To propose a novel anticoagulation treatment protocol utilizing UFH specifically for Japanese COVID-19 patients.
• To enhance the safety of UFH use by minimizing the risk of major bleeding events.
• To align the proposed protocol with current evidence and the specific context of anticoagulation therapy in Japan.

Main Methods:

• Development of a new treatment protocol for UFH administration in COVID-19 patients.
• Consideration of safety parameters to mitigate major bleeding risks.
• Integration of the latest scientific evidence and Japanese clinical context into the protocol design.

Main Results:

• A refined anticoagulation protocol for UFH use in Japanese COVID-19 patients has been developed.
• The protocol emphasizes safety measures to reduce the incidence of major bleeding events.
• The proposed protocol reflects current understanding and practical considerations for anticoagulation in Japan.

Conclusions:

• The proposed UFH protocol offers a tailored approach for managing hypercoagulability in Japanese COVID-19 patients.
• Prioritizing safety and minimizing bleeding are central to the protocol's design.
• This protocol aims to optimize anticoagulation therapy in the context of the ongoing COVID-19 pandemic in Japan.